Every 8-K that Arcadia Biosciences, Inc. (RKDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RKDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RKDA filings page.
Arcadia Biosciences, Inc. (RKDA) reported the results of its September 10, 2026 annual meeting, where holders of 1,259,315 shares of common stock, representing 52.3% of shares outstanding on the record date, were present in person or by proxy. Stockholders elected Gregory D. Waller as a Class II director, approved the potential issuance of common stock upon exercise of the Series A-1 Preferred Investment Options issued in the June 12, 2026 private placement, and approved the new 2026 Omnibus Equity Incentive Plan, which replaces the expired 2015 plan.
Stockholders also approved an amendment authorizing the Board, in its discretion, to implement a reverse stock split at a ratio between 1-for-2 and 1-for-10 any time before June 30, 2027. In addition, they approved, on an advisory basis, executive compensation, ratified Ramirez Jimenez International CPAs as independent registered public accountants for 2026, and approved a proposal allowing adjournment of the meeting if additional time for votes on Proposals 2 or 4 is required.
Arcadia Biosciences, Inc. (RKDA) reports that on August 31, 2026 it received a notice from Nasdaq’s Listing Qualifications Department that its stockholders’ equity no longer meets the Nasdaq Capital Market’s continued listing standard requiring at least $2,500,000 of stockholders’ equity.
Arcadia reported stockholders’ equity of $633,000 as of June 30, 2026 and also does not meet Nasdaq’s alternative market value or net income criteria, so it is currently out of compliance. The common stock continues to trade on the Nasdaq Capital Market while the company has 45 days, until October 15, 2026, to submit a plan to regain compliance. If Nasdaq accepts the plan, Arcadia may receive up to 180 days from the notice date to demonstrate compliance, but there is no assurance the plan will be accepted or that compliance will be achieved, and an appeal process is available if a plan is rejected.
Arcadia Biosciences, Inc. reported second-quarter and first-half 2026 results, showing relatively stable revenues but significantly higher net losses driven largely by financing-related and fair value items. Total revenues were $1.4 million for the quarter and $2.5 million for the first half, down modestly year over year, primarily due to low inventory and shipping delays affecting Zola sales. Second-quarter loss from continuing operations was $0.5 million, but net loss attributable to common stockholders widened to $6.3 million, and to $10.7 million for the first half, reflecting unrealized losses on Above Food stock, a $5.4 million valuation loss on the June 2026 PIPE, a $2.9 million loss on the January 2026 inducement offer, and offering costs, partly offset by gains on warrant and option liabilities.
Operating trends were more favorable: cash used in operating activities was only $319,000 in the quarter, SG&A expenses declined by $1.0 million in the quarter and $1.6 million in the first half versus 2025, and cash and cash equivalents rose to $4.2 million at June 30, 2026, supported by a $4.0 million PIPE and additional financing. Management highlighted strong recent Zola sales momentum and multiple product launches planned through 2027, while also disclosing that additional funding will be required to continue operations and planned activities and that any further equity financing could dilute existing stockholders.
Arcadia Biosciences, Inc. reported that Nasdaq notified the company on August 4, 2026 that its common stock no longer meets the $1.00 per share Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The determination was based on the closing bid price over the 30 consecutive business days from June 22, 2026 to August 3, 2026. The stock will continue trading on Nasdaq under the symbol RKDA during an initial 180-day compliance period ending February 1, 2027. To regain compliance, the closing bid price must be at least $1.00 for at least ten consecutive business days, and Nasdaq may require a longer period. If still noncompliant, Arcadia may qualify for an additional 180-day period, potentially including a reverse stock split. The company states it will monitor its bid price and evaluate options, while cautioning there is no assurance it will regain or maintain Nasdaq compliance.
Arcadia Biosciences updated its 2025 executive pay disclosure after approving a discretionary cash bonus for Chief Executive Officer and Interim Chief Financial Officer Thomas J. Schaefer. For 2025, Schaefer received salary of $260,000, a cash bonus of $169,000, option awards valued at $40,001, other compensation of $4,057 and total compensation of $473,058. No other named executive officers received a 2025 bonus under the company’s Executive Incentive Bonus Plan.
The Board also set the 2026 annual meeting of stockholders for September 10, 2026. Shareholders wishing to nominate directors or submit proposals, including those intended for proxy inclusion under Rule 14a-8, must ensure the company receives proper notice by the close of business on July 13, 2026 at its Dallas headquarters, in accordance with its Bylaws and SEC rules.
Arcadia Biosciences entered into and closed a $4 million private placement of pre-funded warrants and preferred investment options with an institutional accredited investor, priced at-the-market under Nasdaq rules. The investor purchased pre-funded warrants and Series A-1 and A-2 preferred investment options linked to up to 3,883,496 shares of common stock each, at a purchase price of about $1.03 per unit. The pre-funded warrants are immediately exercisable at $0.0001 per share with no expiration until fully exercised, while the Series A-1 and A-2 options carry a $0.91 exercise price with five-year and two-year terms, respectively, subject to stockholder approval and registration timing. Arcadia agreed to file resale registration statements, observe issuance restrictions and potential cashless exercise features, and granted H.C. Wainwright placement fees, expense reimbursements, and 271,845 placement agent options. Net proceeds are earmarked for working capital and general corporate purposes.
Arcadia Biosciences reported first-quarter 2026 results showing growth in its Zola coconut water brand but a sharp swing back to losses. Product revenues were $1.1 million, down 8% from $1.2 million a year earlier, mainly because 2025 benefited from a one-time revenue reserve release.
Total operating expenses rose to $1.9 million from $670,000, as the prior year included a $750,000 gain on sale of patent portfolios and a $1.0 million gain from a change in contingent consideration. The company posted a net loss attributable to common stockholders of $4.4 million, or $2.11 per share, compared with net income of $2.6 million, or $1.90 per share, in the first quarter of 2025.
Management highlighted that Zola volumes increased 18% and that selling, general and administrative expenses were at their lowest level in the company’s public history. Arcadia ended March 31, 2026 with cash of $954,000 and short-term investments of $2.8 million, supported by approximately $2.1 million of gross proceeds from exercises of preferred investment options and $2.1 million from a January 2026 warrant inducement offer. The company cautioned it will require additional funding in the near future to continue operations and planned activities.
Arcadia Biosciences, Inc. filed an 8‑K announcing that its audit committee dismissed Deloitte & Touche as independent auditor and appointed Ramirez Jimenez International CPAs (RJI), effective March 30, 2026. Deloitte’s reports on the 2024 and 2025 financial statements included an explanatory paragraph about the company’s ability to continue as a going concern, citing accumulated deficit, recurring net losses, net cash used in operations and limited resources.
The company also reiterates previously disclosed material weaknesses in internal control over financial reporting, including insufficient segregation of duties in the financial close process and insufficient information system controls such as access and change management, driven in part by reduced employee headcount. The 8‑K states there were no disagreements with Deloitte on accounting principles, disclosure, or audit scope, and that Deloitte has been authorized to respond fully to RJI’s inquiries. A confirming letter from Deloitte to the SEC is attached as an exhibit.
Arcadia Biosciences reported smaller losses for 2025 but faces liquidity pressure. Total revenues were $4.9M, down slightly from $5.0M, while Zola® coconut water revenues grew 17% year over year. Selling, general and administrative costs fell about 27%, helping reduce net loss attributable to common stockholders to $2.3M from $7.0M.
Cash and cash equivalents dropped to $259K as of December 31, 2025, from $4.2M a year earlier. A proposed business combination with Roosevelt Resources was terminated, and the company raised approximately $2.1M in gross proceeds from the exercise of preferred investment options. Management states it will require additional funding in the near future and may pursue equity or debt financings or asset transactions, which could dilute existing shareholders.
Arcadia Biosciences, Inc. reported that two members of its board of directors, Albert D. Bolles, Ph.D. and Deborah Carosella, resigned from the board effective February 4, 2026.
Bolles served on the Compensation Committee, while Carosella served on both the Compensation Committee and the Nominating and Governance Committee. The company stated that their resignations were not due to any disagreement with the company or its board regarding operations, policies, practices, or financial statements. Both former directors agreed to remain available to assist the company in an advisory capacity.
Arcadia Biosciences entered inducement agreements on January 9, 2026 with certain investors to encourage exercise of existing preferred investment options. Holders agreed to exercise options for 808,595 shares of common stock, with the exercise price cut from $9.00 to $2.575 per share. The closing on January 12, 2026 generated aggregate gross proceeds of about $2.1 million, which the company plans to use for working capital and general corporate purposes.
In exchange, Arcadia issued new unregistered preferred investment options to buy up to 1,617,190 shares at $2.325 per share and placement agent options for 56,602 shares at $3.2188, both exercisable immediately and expiring 30 months after a resale registration statement becomes effective. The new and placement agent options include 4.99% or 9.99% beneficial ownership caps, adjustment provisions, and cashless exercise features if a resale registration is not effective. The company agreed not to issue most additional equity for 45 days after closing and not to enter variable rate transactions for one year.
Arcadia Biosciences furnished an update on its business by announcing that it issued a press release with financial results for the third quarter ended September 30, 2025. The press release (Exhibit 99.1) and detailed third‑quarter financial information (Exhibit 99.2) are included as exhibits and are being furnished, not filed, under the Exchange Act.
The company also reiterated details of its proposed all‑stock combination with Roosevelt Resources, LP, under which Arcadia will issue shares of its common stock to Roosevelt’s partners in exchange for all equity interests in Roosevelt. Arcadia has filed a Registration Statement on Form S‑4 (File No. 333‑284972) and a pre‑effective amendment; after the S‑4 is declared effective, it intends to mail a definitive proxy statement/prospectus to stockholders for their consideration of matters related to the transaction.
Arcadia Biosciences set its 2025 annual meeting of stockholders for December 19, 2025. The time, location, and matters to be considered will appear in the definitive proxy statement to be filed with the SEC.
The company updated stockholder deadlines due to the meeting date shift. To be timely, nominations for director and stockholder proposals intended for inclusion in the proxy, or other proposals for consideration at the meeting, must be received by the close of business on November 3, 2025 at Arcadia Biosciences, Inc., 5956 Sherry Lane, 20th Floor, Dallas, Texas 75225, Attention: Corporate Secretary, and must comply with Rule 14a-8 and the company’s Bylaws.
The annual meeting and related proxy are separate from any special meeting relating to the all‑stock Exchange with Roosevelt Resources, LP. Arcadia previously filed an S‑4 (File No. 333‑284972) including a preliminary proxy statement/prospectus; a definitive version will be mailed after effectiveness.
Arcadia Biosciences, Inc. disclosed that its chief financial officer and principal accounting officer, Mark Kawakami, has tendered his resignation as an officer and employee, effective September 12, 2025. The company states that his resignation is not due to any disagreement with Arcadia or its independent auditors on operations, policies, financial statements, or accounting practices, and notes he may assist after his departure as an advisor or consultant if requested.
Effective upon his resignation, the Board has appointed President and Chief Executive Officer Thomas J. Schaefer as Interim Chief Financial Officer and principal accounting officer. Schaefer previously served as Arcadia’s Chief Financial Officer from January 2023 until becoming President and CEO in July 2024, and his selection was not made pursuant to any arrangement with another person. His compensation is unchanged.
The filing also reiterates details of Arcadia’s proposed all-stock exchange transaction with Roosevelt Resources, LP, for which a Form S-4 registration statement has been filed and amended, and urges investors to read the registration statement and proxy statement/prospectus once available, as they will contain important information about the transaction and related risks.
Arcadia Biosciences, Inc. filed a current report to furnish its financial results for the second quarter ended June 30, 2025. The company issued a press release and detailed financial information, attached as Exhibits 99.1 and 99.2, covering second-quarter 2025 performance and business highlights.
The report also reiterates the previously announced plan for an all-stock exchange transaction with Roosevelt Resources, LP under a Securities Exchange Agreement. Arcadia has filed a Registration Statement on Form S-4, including a preliminary proxy statement/prospectus, and a pre-effective amendment filed on July 31, 2025. After the Registration Statement is declared effective, Arcadia intends to mail a definitive proxy statement/prospectus to stockholders for a vote on the proposed transaction.